Corporate
-
-
Janssen Initiates FIRST, a Novel Study to Evaluate the Benefit of Caregiver Education in Improvement of Outcomes for Patients with Serious Mental Illness
New Study Examines Link between Caregiver Education and Patient Outcomes -
Your Story, Your HIV Wisdom™ Brings Together HIV Voices and Supports HIV Community Organizations
Notable HIV Advocates Highlight Perspectives of People Living with or Affected by HIV to Leverage Shared Support and Self-Expression -
New Global Real-World Data from Atrial Fibrillation Studies Confirm the Safety Profile of XARELTO®
Global evidence from EXPLORER research program reports real-world bleeding rates in XARELTO® (rivaroxaban) patients with non-valvular atrial fibrillation -
CELLSEARCH® System Recognized as Landmark Innovation in Cancer Research
Seminal Study included in list of Most Significant Publications of past 20 years in Clinical Cancer Research. -
-
Phase 2B Findings Published In The New England Journal Of Medicine Demonstrate Significant Efficacy Of Guselkumab In Treatment Of Moderate To Severe Plaque Psoriasis
Guselkumab, an anti-interleukin-23 monoclonal antibody, showed improvements in primary and secondary endpoints compared with placebo and active comparator adalimumab, an anti-tumor necrosis factor-alpha agent -
Daratumumab Expanded Access Program Open to Eligible U.S. Patients with Heavily Pre-Treated Multiple Myeloma
Janssen, with support from the Multiple Myeloma Research Foundation, opens EAP to help patients in immediate need of new treatment options -
Investigational HIV Vaccine Regimen Shows Encouraging Results in Non-Human Primates
Pre-Clinical Data Published in Science Forms Basis for Early Human Clinical Trials